Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation

BACKGROUND: Although patients taking non-vitamin K antagonist oral anticoagulants (NOACs) do not require routine coagulation monitoring, high-risk patients require monitoring to assess pharmacodynamics. METHODS: We measured (1) anti-factor Xa activity (AXA), using chromogenic assay with the HemosIL...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Kozue, Tachibana, Hideaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759124/
https://www.ncbi.nlm.nih.gov/pubmed/26949430
http://dx.doi.org/10.1016/j.joa.2015.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759124/
https://www.ncbi.nlm.nih.gov/pubmed/26949430
http://dx.doi.org/10.1016/j.joa.2015.08.001

Ejemplares similares